TOKYO, Jun 16 (Pulse News Wire) – StemRIM Inc. (4599.T) announced today that a patent application related to a novel treatment utilizing its regenerative medicine drug Ledasumtid (HMGB1 fragment peptide) for fatty liver and non-alcoholic conditions has been registered in Russia.
The development was derived from technology licensed to Shionogi & Co., Ltd. Ledasumtid, developed under project code S5,151, targets treatments for fatty liver disease and non-alcoholic steatohepatitis (NASH). The patent application number is 2,024,111,536. The invention's title is “Medicine for Treating Fatty Liver and Non-Alcohol Sei Shibou Kan'En”. The applicants include StemRIM Inc., Osaka University, and Niigata University.
This patent expansion aims to broaden the therapeutic scope of Ledasumtid, securing potential for developing medicinal treatments against fatty liver and NASH in Russia. Fatty liver disease involves excessive fat accumulation in the liver, often asymptomatic but linked to lifestyle diseases. NASH progresses due to factors such as obesity and diabetes, leading to inflammation and fibrosis, potentially causing cirrhosis or liver cancer. Effective pharmaceutical treatments currently lack, making new therapies and regenerative medical approaches urgent. There will be no impact on fiscal year 2026 July-term consolidated performance; however, StemRIM will promptly disclose any significant developments arising from this patent.
🟢 Confidence: High AI-translated content.